KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Accumulated Expenses (2017 - 2025)

Historic Accumulated Expenses for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $4.7 million.

  • Bionano Genomics' Accumulated Expenses fell 2000.68% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 2000.68%. This contributed to the annual value of $5.6 million for FY2024, which is 3026.33% down from last year.
  • According to the latest figures from Q3 2025, Bionano Genomics' Accumulated Expenses is $4.7 million, which was down 2000.68% from $3.4 million recorded in Q2 2025.
  • Bionano Genomics' Accumulated Expenses' 5-year high stood at $11.7 million during Q3 2022, with a 5-year trough of $3.4 million in Q2 2025.
  • Moreover, its 5-year median value for Accumulated Expenses was $8.1 million (2023), whereas its average is $7.7 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 16902.51% in 2021, then plummeted by 6430.0% in 2025.
  • Over the past 5 years, Bionano Genomics' Accumulated Expenses (Quarter) stood at $8.6 million in 2021, then rose by 22.4% to $10.6 million in 2022, then fell by 23.34% to $8.1 million in 2023, then plummeted by 30.26% to $5.6 million in 2024, then dropped by 16.58% to $4.7 million in 2025.
  • Its Accumulated Expenses was $4.7 million in Q3 2025, compared to $3.4 million in Q2 2025 and $3.9 million in Q1 2025.